This article describes the role of generics in the Australian prescription drug market and patterns of business activity in this dynamic market segment. The Pharmaceutical Benefits Scheme (PBS) is the central mechanism for the supply of prescription medicines. PBS prices are arrived at through cost-effectiveness analyses comparing new products against already available products and therapies. In this system, prices do not operate effectively as incentives for consumers or prescribers to choose generics, and their market share was historically marginal. In recent years, generics suppliers achieved a growing market share through discounts (trading terms) to pharmacists. It is estimated that around 30% of PBS scripts, representing around 15% of PBS sales by value, are now filled with generics. Complex changes to the PBS were introduced in 2007, to be phased in over the period to 2012, aimed at increasing the scope for cost benefits to the government, and to lesser extent consumers, from the expanding availability of generic medicines.
been searching for ways for tax payers and consumers to benefit, to a greater extent than hitherto, from low cost generics. The result is a major policy reorientation in 2007 aimed at driving down generics prices. This article briefly explains these changes, against the background of a sketch of regulatory arrangements and the business of generics in Australia. The focus is on the PBS market, which represents the bulk of prescription drug sales (public hospital tendering arrangements have long ensured a dominant role of generics in that sector) 9 .
Prescription drug regulation and the role of generics Australia's system of drug regulation encompasses two major steps. Medicines must first be entered on the Australian Register of Therapeutic Goods (ARTG) following approval by the Therapeutic Goods Administration (TGA) for acceptable quality, safety and efficacy. Generic products are assessed by the TGA for bioequivalence with the originator brand through a process of rigorous scientific evaluation normally completed within 45 working days 10, 11 . For biosimilars, the TGA has adopted the guidelines of the European Medicines Agency (EMEA) and each submission is assessed on a case-by-case basis. Omnitrope (supplied by Sandoz/Novartis) was the first biosimilar introduced (in November 2005) to the Australian market 12 . Notwithstanding the efficiency and high reputation of TGA procedures, regulatory requirements are considered relatively inhospitable to the Introduction Prescription drug sales in Australia at around US$8 billion constitute a small share of the US$800 billion global market 1 .
Yet Australia is a high income economy with strict regulatory requirements closely monitored by drug policy analysts and the pharmaceutical industry for generics also in Australia [5] [6] [7] . Recent assessments suggest that around 30% of PBS prescriptions are dispensed with a generic, representing around 15% of the value of sales 8 . In response to escalating health costs, and patents expiring on many big products, the Department of Health and Ageing (DoHA) has generics sector. Patent rights extend beyond those mandated by the Agreement on Trade-Related aspects of Intellectual Property Rights (TRIPS) to include a five-year data exclusivity period, precluding data submitted to the TGA relating to a pharmaceutical product from being used by another company in applying for marketing approval until five years after approval of the original product. Moreover, patent extensions of up to five years are available for pharmaceutical standard patents, under certain circumstances, to compensate for delays in the marketing approval process. Such extensions are not available in countries such as New Zealand, Canada, South Africa, China or India 13, 14 . Mylan, the parent company of market-leading Alphapharm, considers consequent delays in patent expiries to be 'somewhat responsible for under-penetration of generic products' in Australia 15 . Generics can also not be produced for exports whilst patents still apply in Australia. This latter constraint "places Australian generic manufacturers at such a disadvantage, even relative to generic manufacturers located in the US, Canada or Western Europe, that global companies are actively choosing their non-Australian facilities to manufacture new products" Where a prescription has been issued for a product with a price premium, the pharmacist can at the patient's request dispense another brand of the same medicine, unless the prescribing doctor has specifically indicated otherwise. About 55% of all PBS prescriptions are substitutable, yet only 33% are substituted -the difference points to the potential for further generics growth through substitution (even in the absence of additional medicines coming off patents) 23 .
A conundrum for the government which was only marginally mitigated by the brand premium policy (introduced in 1990) and the therapeutic group premium policy (in 1998) is the absence of incentives for PBS suppliers to compete on price, with reference pricing ensuring that any price cuts offered to the PBS flow through to all other suppliers of the same or similar products 5 . Rather than competing on price, generics suppliers in the past decade gained access to the PBS market though discounts or trading terms to pharmacists, typically around 30% and often 50% or more. In other words, pharmacists have been reimbursed by the government at prices well above the prices actually paid. From a pharmacy perspective, such trading terms came to be considered standard business deals rewarding efficiencies and scale 
The generics business in Australia
It is estimated, as noted, that around 30% of PBS prescriptions are dispensed with a generic, representing between 10% and 15% of the value of PBS sales 24, 25 . But reliable market information is not readily available. The detailed data on the community pharmacy market collected by the PGA is not publicly released, but used selectively for lobbying purposes. For their part, generics suppliers share with the PGA an interest in withholding information about market shares and pharmacy trading terms. The lack of transparency is reinforced by increasingly blurred lines globally and in Australia between the originator and generics sectors 26 . Several leading brand companies are also major generics suppliers, most significantly Novartis through its Sandoz division. The use of authorized or pseudo-generics is common practice, that is, products cross-licensed by a brand company to a specialized generics supplier, or marketed by an originator company by a subsidiary under a different name 27 . Around 20% of all generics available in Australian community pharmacies are estimated to be in this category, which includes re-packaged versions of major products such as Ventolin, Losec, Valium, Normison, Augmentin and Prozac. Repackaged is the key term -pseudo-generics are not bioequivalent, alternative brands but by definition identical to the originator product, typically from the same production line 28 . The extent of this practice can be gauged from the estimate that 'of the 300-plus products sold by Alphapharm, the nation's biggest generic drug company … a quarter is made by other companies' 29 . Pseudogenerics are the subject of legal and political controversy in the USA but in Australia it is a phenomenon yet to be systematically investigated 30 .
There are around ten companies supplying generics to the PBS, with two firms dominating. The Generic Medicines industry Association (GMiA) claims its six member companies supply 98% of generic prescriptions. Alphapharm has a market share of around 60% and Sigma about 20% 15 . Only three firmsAlphapharm, Sigma and Hospira -undertake manufacturing or R&D associated with manufacturing in Australia, the others are engaged solely in the marketing of imported final drugs 16 . Generics suppliers in Australia operate in a growing and dynamic market but one characterized by lack of transparency and distortions such as dominance by a few major players and shadowy cross-licensing arrangements. Consolidation is happening in the international generics sector at a rapid pace and most firms in Australia are now linked into global corporations drawing on manufacturing in locations such as India 26 . The government is presently seeking to address some of the problems of the generics market through major changes to the PBS.
PBS reform
The key premise of the complex reform legislation introduced in 2007 is that generics prices have been too high and the aim of is to ensure better value for taxpayers [31] [32] [33] . The importance of this policy shift is highlighted by the looming expiry of patents on more than 100 PBS drugs in the next decade. In 2006 the government foresaw PBS savings from these changes of AUS$3 billion over ten years, but a recent estimate suggests that savings may exceed AUS$7 billion over that period 25 . Prices of generic drugs will be cut, pharmacy trading terms will be scaled back, and real prices paid by pharmacies made transparent through the phasing in of price disclosure requirements. The legislation was preceded by negotiations with the different sections of the industry behind closed doors. The gain for Medicines Australia, representing originator companies, is a weakening of the reference pricing system, a concession made by the government in exchange for the brand industry's acceptance of measures ensuring lower generics prices and incentives for greater uptake of generics by pharmacists. This is achieved through the de-linking, for PBS pricing purposes, of patented products from generics, even where delivering similar therapeutic benefits, unless deemed 'interchangeable at the patient level' 33, 34 .
This Prescribers figure only peripherally in the present drive for greater uptake of cheaper generics, while the government has allocated some additional resources to a campaign by the National Prescribing Service to inform consumers about generics 37 . But the reform emphasis is squarely on the mandatory price cuts and associated measures to achieve greater generics pricing transparency and on changes in incentives for pharmacists. The community pharmacy sector is very sensitive to its dependence on regulatory protection and the volume and value of PBS products dispensed. The PGA viewed with apprehension the prospect of lower generics prices and the scaling back of trading terms and is perennially concerned about the possibility of more far-reaching regulatory changes 24, 38 . But community pharmacy reform has been deferred by the government, possibly to be revisited in context of negotiations with the PGA about arrangements to follow the Fourth Community Pharmacy Agreement, which expires in June 2010 • A 15% increase in dispensing fees and adjustments to pharmacy mark-ups from 1 August 2008. (25) It was reported in March 2009 that generic substitution had increased by around 20% following PBS changes coming into effect in August 2008 'with 29% of pharmacists increasing their substitution to some degree' 8 . Recent changes also includes the establishment of an industry-government Access to Medicines Working Group, to provide an avenue for direct communications between Medicines Australia and DoHA, to consider issues related to the PBS, including matters such as the future of pharmacy compensation arrangements and consumer education programs to promote generics 31 .
It is too early to assess the implications of the F1-F2 reform and related PBS changes for different industry segments. The PGA remains uneasy about the future of community pharmacy while Medicines Australia appears broadly satisfied with recent developments. For its part, the generics sector reports declines in revenues and profitability as a result of price cuts. Yet medium and long term prospects for generics suppliers remain positive as PBS reforms and patent expiries accelerate the growth of the market share of generics 15 . According to Ascent Pharmaceuticals "The one-off effect of the PBS reforms will allow the industry to grow profitably going forward from these new price levels. This along with increased generic substitution and the introduction of new generic medicines is expected to bring strong margin value growth to the sector. The market outlook for generic pharmaceuticals remains strong with generic substitution in Australia expected to grow strongly over the next few years" 40 .
Concluding remarks
The generics sector is an established and growing segment of the Australian drug market and the PBS changes initiated in 2007 will accelerate this process. Following the introduction in 1994 of brand substitution, the major impediment to the growth of the generics sector, due to small price differentials, was the absence of incentives for doctors, pharmacists and consumers to choose generics. Recent changes do not significantly address the role of prescriber and consumer incentives, but will make dispensing pharmacists more inclined to support generic substitution. However the direct cost benefits to government are arrived at through mandatory price cuts and price disclosure requirements. These steps in conjunction with coming patent expiries will significantly increase, over the next decade, the market share of generics from the present level of around 30% of dispensed PBS drugs. But the brand industry remains strongly entrenched, as reflected in intellectual property rights legislation unfavorable to the generics sector and the design of the F1/F2 reform. Moreover, the generics market is distorted by the dominance of a small group of suppliers and cross-licensing (pseudo-generic) arrangements with the major brand companies.
